welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
unknown status
Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping
study id #: NCT01772043
condition: Duchenne Muscular Dystrophy
status: unknown
purpose:We will utilize the Cooperative International Neuromuscular Research Group (CINRG) network to collect and store tissue and blood from patients with Duchenne muscular dystrophy (DMD) with specific genetic mutations within the dystrophin gene that could be treated by antisense oligonucleotide (AO) drugs.
mechanism of action: No pharmaceutical intervention
results: https://clinicaltrials.gov/ct2/show/results/NCT01772043
last updated: November 22, 2018
study details
study contacts
rareRelated
-
Phase 1/2 Study in Boys With Duchenne Muscular DystrophyThe MoveDMD study is a 3-part, Phase 1/2...
-
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne M...This is a Phase 2 randomized, 2-period, ...
-
Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of DMD and BMDLongitudinal prospective observational s...
-
Assessment of Cardiopulmonary Function in Duchenne Muscular DystrophyThis study seeks to develop and validate...
-
Study of Eteplirsen in Young Patients With DMD Amenable to Exon 51 SkippingThis is a multicenter, open-label, dose-...
-
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Musc...This is a multi-center, randomized, doub...
-
The Effect of Kinesiology Taping on Balance in Duchenne Muscular DystrophyInvestigators investigated that the effe...
-
MDA Releases Duchenne Fact Sheet, Survey Results Pointing to Need for Knowledge of Clinical Trials and Genetic TestsCiting a persistent need for new treatme...
-
There’s No Straight Line in Drug DevelopmentToday’s FDA disapproval of Sarepta’s...
-
Rimeporide: safety, tolerability and pharmacokinetic results from a phase Ib study in DMD boys as well as explorator...In Duchenne muscular dystrophy, impaired...
-
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular DystrophyAntisense Therapeutics today announced d...
-
Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilo...Wave Life Sciences Ltd., a biotechnology...
